US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Latigo Biotherapeutics Inc

23.93

+0.87003.77%

Post-market: 23.930.00000.00%16:10 EDT

Volume:429.75K

Turnover:10.31M

Market Cap:1.59B

PE:-14.28

High:24.80

Open:23.14

Low:23.09

Close:23.06

52wk High:25.93

52wk Low:17.22

Shares:66.30M

Float Shares:22.12M

Volume Ratio:1.82

T/O Rate:1.94%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6760

EPS(LYR):-129.2325

ROE:--

ROA:--

PB:-5.75

PE(LYR):-0.19

Loading ...

Overview Company News Filings

Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY

Benzinga Earnings

Latigo Biotherapeutics Posts Q2 FY26 Net Loss of $25.8 Million; G&A Expenses Rise 64.29% to $4.6 Million

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

THOMSON REUTERS

Latigo Biotherapeutics Price Target Announced at $36.00/Share by Leerink Partners

Latigo Biotherapeutics initiated with a Buy at Jefferies

Guggenheim Initiates Latigo Biotherapeutics at Buy With $50 Price Target

MT Newswires Live

Latigo Biotherapeutics, Inc. : Leerink Partners Initiates Coverage with Outperform Rating; Target Price $36

THOMSON REUTERS

Latigo Biotherapeutics initiated with a Buy at Goldman Sachs

Latigo Biotherapeutics Files Initial Beneficial Ownership Statement for Sanofi

Foresite’s James Tananbaum Acquires 140,000 Latigo Biotherapeutics Shares for $2.52 Million

Latigo Biotherapeutics Completes IPO and Updates Governance

Latigo Biotherapeutics Adopts Amended and Restated Bylaws Tied to IPO Close

U.S. Stocks on the MOVE-Atlassian, Macerich, DoubleVerify

Non-Opioid Pain Drug Developer Soars Over 14% in Market Debut

Stock Track | Latigo Biotherapeutics Soars 16.67% in Nasdaq Debut After Upsized $345.6 Million IPO

Latigo Poised to Open Higher in NASDAQ Debut After Upsized $345.6 Million IPO

Latigo Biotherapeutics Ups IPO to 19.2 Million Shares

Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/LTGO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"LTGO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LTGO\",,,,,undefined,":{"symbol":"LTGO","market":"US","secType":"STK","nameCN":"Latigo Biotherapeutics Inc","latestPrice":23.93,"timestamp":1789675200000,"preClose":23.06,"halted":0,"volume":429747,"hourTrading":{"tag":"盘后","latestPrice":23.93,"preClose":23.93,"latestTime":"16:10 EDT","volume":19018,"amount":455100.74,"timestamp":1789675804247,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03772766695576761,"floatShares":22121291,"shares":66299347,"eps":-1.676,"marketStatus":"Post-Mkt","change":0.87,"latestTime":"09-17 16:18:38 EDT","open":23.14,"high":24.8,"low":23.085,"amount":10306442,"amplitude":0.074371,"askPrice":24.4,"askSize":81,"bidPrice":23.46,"bidSize":86,"shortable":3,"etf":0,"ttmEps":-1.676,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789689600000},"marketStatusCode":4,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":23.06,"postHourTrading":{"tag":"盘后","latestPrice":23.93,"preClose":23.93,"latestTime":"16:10 EDT","volume":19018,"amount":455100.74,"timestamp":1789675804247,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.818451},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LTGO\",,,,,undefined,":{"symbol":"LTGO","floatShares":22121291,"roa":"--","roe":"--","lyrEps":-129.23255,"volumeRatio":1.818451,"shares":66299347,"dividePrice":0,"high":24.8,"amplitude":0.074371,"preClose":23.06,"low":23.085,"week52Low":17.2201,"pbRate":"-5.75","week52High":25.93,"institutionHeld":0,"latestPrice":23.93,"committee":0.02994,"eps":-1.676,"divideRate":0,"volume":429747,"delay":0,"ttmEps":-1.676,"open":23.14,"prevYearClose":18,"prevWeekClose":22.15,"prevMonthClose":22.02,"prevQuarterClose":18,"fiveDayClose":21.54,"twentyDayClose":20.94,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LTGO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LTGO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LTGO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1788580800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LTGO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LTGO","date":"2026-09-16","current":-14.278043,"percent":0.148148,"low":-14.220252,"twenty":-13.675766,"median":-12.593455,"eighty":-11.046861,"high":-10.257227,"avg":-12.3801,"sd":1.213178,"marketCap":1525547974},"quantilePoints":[{"date":"2026-08-07","current":-10.257227,"twenty":-10.257227,"median":-10.257227,"eighty":-10.257227,"marketCap":1140357438},{"date":"2026-08-14","current":-11.41033,"twenty":-11.020695,"median":-10.545739,"eighty":-10.380784,"marketCap":1268554881},{"date":"2026-08-21","current":-12.172536,"twenty":-11.41033,"median":-11.020695,"eighty":-10.534363,"marketCap":1353293842},{"date":"2026-08-28","current":-14.220252,"twenty":-12.724282,"median":-11.393266,"eighty":-10.557115,"marketCap":1580950750},{"date":"2026-09-04","current":-12.786851,"twenty":-12.786851,"median":-12.172536,"eighty":-10.978035,"marketCap":1421590914},{"date":"2026-09-11","current":-12.849682,"twenty":-13.626145,"median":-12.513822,"eighty":-11.012163,"marketCap":1428087934},{"date":"2026-09-16","current":-13.72661,"twenty":-13.675766,"median":-12.593455,"eighty":-11.046861,"marketCap":1525547974}],"updateTime":1789676318116},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LTGO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664804677","title":"Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2664804677","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664804677?lang=en_us&edition=fundamental","pubTime":"2026-09-04 05:04","pubTimestamp":1788469452,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly losses of $(27.59) per share. This is a 24.45 percent increase over losses of $(36.52) per share from the same period last year. The company reported $0.00 in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/61617346/latigo-biotherapeutics-q2-eps-27-59-36-52-yoy-sales-0-00-same-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664016848","title":"Latigo Biotherapeutics Posts Q2 FY26 Net Loss of $25.8 Million; G&A Expenses Rise 64.29% to $4.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664016848","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664016848?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:17","pubTimestamp":1788466620,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics posts Q2 FY26 net loss of $25.8 million; G&A expenses rise 64.29% to $4.6 millionLatigo posted a net loss of USD 25.8 million for Q2 2026, unchanged from Q2 2025.R&D expense sli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL9C61mB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664809283","title":"Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2664809283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664809283?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:05","pubTimestamp":1788465902,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA4YKY7F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664432865","title":"Latigo Biotherapeutics Price Target Announced at $36.00/Share by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2664432865","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664432865?lang=en_us&edition=fundamental","pubTime":"2026-09-02 02:47","pubTimestamp":1788288420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LTGO/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853864","title":"Latigo Biotherapeutics initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853864?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:25","pubTimestamp":1788258349,"startTime":"0","endTime":"0","summary":"Jefferies initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $50 price target The firm believes LTG-001 will show at least a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/latigo-biotherapeutics-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/latigo-biotherapeutics-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LTGO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664398858","title":"Guggenheim Initiates Latigo Biotherapeutics at Buy With $50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2664398858","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664398858?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:13","pubTimestamp":1788257583,"startTime":"0","endTime":"0","summary":"Guggenheim Initiates Latigo Biotherapeutics at Buy With $50 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664083071","title":"Latigo Biotherapeutics, Inc. : Leerink Partners Initiates Coverage with Outperform Rating; Target Price $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2664083071","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664083071?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:05","pubTimestamp":1788257140,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTGO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883471","title":"Latigo Biotherapeutics initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883471?lang=en_us&edition=fundamental","pubTime":"2026-09-01 16:30","pubTimestamp":1788251407,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $73 price target Latigo is clinical-stage biotechnology com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/latigo-biotherapeutics-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/latigo-biotherapeutics-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1868836914.USD","DARP","LU0210536198.USD","FWD","LU2237443622.USD","XT","LU0106831901.USD","LU2237443549.SGD","LU1894683348.USD","LU1868837136.USD","BBP","BK4585","IEIH","BBC","JDOC","RSPH","IE0002270589.USD","LU2237443382.USD","GSX","FHLC","IE00BFXG1179.USD","BK4007","LU1144417596.USD","LU2471134796.USD","SYNB","IE00B19Z3B42.SGD","BK4127","IBB","LU1868836591.USD","LU1668664300.SGD","LU0868494617.USD","LU0942090050.USD","BK4516","IE00BSNM7G36.USD","BK4552","AGNG","BK4504","LU0096364046.USD","LU0345770993.USD","LU0251131958.USD","IE0004086264.USD","BK4550","LU2237443895.HKD","LU2471134523.USD","LTGO","LU2896262040.SGD","LU2237438978.USD","LU1868836757.USD","IE0004091025.USD","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972487","title":"Latigo Biotherapeutics Files Initial Beneficial Ownership Statement for Sanofi","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972487","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972487?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:10","pubTimestamp":1786536651,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics files initial beneficial ownership statement for SanofiSanofi filed a Form 3 disclosing 10% ownership in Latigo Biotherapeutics as of Aug. 6, 2026.Indirect beneficial ownership ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL74rSy8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658785950","title":"Foresite’s James Tananbaum Acquires 140,000 Latigo Biotherapeutics Shares for $2.52 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658785950","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658785950?lang=en_us&edition=fundamental","pubTime":"2026-08-11 08:00","pubTimestamp":1786406448,"startTime":"0","endTime":"0","summary":"Foresite’s James Tananbaum acquires 140,000 Latigo Biotherapeutics shares for $2.52 millionLatigo Biotherapeutics director James B. Tananbaum reported acquiring 3,562,984 shares of common stock throug","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL6456dW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Foresite’s James Tananbaum Acquires 140,000 Latigo Biotherapeutics Shares for $2.52 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658957994","title":"Latigo Biotherapeutics Completes IPO and Updates Governance","url":"https://stock-news.laohu8.com/highlight/detail?id=2658957994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658957994?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:20","pubTimestamp":1786400419,"startTime":"0","endTime":"0","summary":"An update from Latigo Biotherapeutics, Inc. ( ($LTGO) ) is now available. On August 10, 2026, Latigo Biotherapeutics, Inc. closed its initial publi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/latigo-biotherapeutics-completes-ipo-and-updates-governance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/latigo-biotherapeutics-completes-ipo-and-updates-governance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KCE","LTGO","REDS","BK4127","FRHC","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658956232","title":"Latigo Biotherapeutics Adopts Amended and Restated Bylaws Tied to IPO Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2658956232","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658956232?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:04","pubTimestamp":1786392261,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics adopts amended and restated bylaws tied to IPO closeLatigo Biotherapeutics adopted amended and restated bylaws effective Aug. 10, 2026 in connection with its IPO closing.It also","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL3yN7JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657401316","title":"U.S. Stocks on the MOVE-Atlassian, Macerich, DoubleVerify","url":"https://stock-news.laohu8.com/highlight/detail?id=2657401316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657401316?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:39","pubTimestamp":1786120748,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Atlassian, Macerich, DoubleVerifyAug 7 (Reuters)-Wall Street's main indexes were on track for strong weekly gains on Friday after data showed the U.S. economy unexpectedly","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL6N4440XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COHR","NET","TRGP","SEZL","YJ","STX","ABNB","SG","STEP","BNL","RKT","SEDG","ASIX","FSLR","BETR","MCHP","BLND","ENPH","RWAY","VST","WEAV","EXFY","XOM","REPL","TTD","VLO","INVX","RUN","ATGL","AU","CVRX","DV","RMD","TEAM","CVX","TTWO","LTGO","UAA","WEN","DOCS","MB","PN","XPOF","BLSM","MAC","VATE","NEM","ACMR","MTW","FLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177328700","title":"Non-Opioid Pain Drug Developer Soars Over 14% in Market Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1177328700","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177328700?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:28","pubTimestamp":1786120091,"startTime":"0","endTime":"0","summary":"On Friday, Latigo Biotherapeutics (LTGO.US) made its public market debut, with shares surging more than 14% to $20.53 at the time of writing.The company is a developer of non-opioid pain medications...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185286978","title":"Stock Track | Latigo Biotherapeutics Soars 16.67% in Nasdaq Debut After Upsized $345.6 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1185286978","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185286978?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:42","pubTimestamp":1786117348,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics (LTGO) surged 16.67% in intraday trading on Friday, marking a strong debut on the Nasdaq. The clinical-stage biopharmaceutical company's stock opened well above its initial...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641620","title":"Latigo Poised to Open Higher in NASDAQ Debut After Upsized $345.6 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641620","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641620?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:56","pubTimestamp":1786110990,"startTime":"0","endTime":"0","summary":"BUZZ-Latigo poised to open higher in Nasdaq debut after upsized $345.6 million IPO** Drug developer Latigo BiotherapeuticsLTGO.Oon track to open above offer price in Nasdaq debut after $345.6 million ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL6N4440OC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","BK4550","LU1868836757.USD","LU2237443465.HKD","LU2237443622.USD","LU0061475181.USD","LU1791807156.HKD","LU2237443382.USD","LU2265009873.SGD","BK4552","IE00BSNM7G36.USD","IE00BFXG1179.USD","LU0106831901.USD","LU1668664300.SGD","LTGO","LU0868494708.USD","LU2471134879.HKD","LU2471134952.CNY","IE0034235188.USD","LU1868836914.USD","BK4585","LU2237443895.HKD","LU2237443549.SGD","LU2471134796.USD","IE0002270589.USD","LU0048573561.USD","IE0004086264.USD","BK4588","LU1804176565.USD","LU0251131958.USD","LU0942090050.USD","BK4504","BK4516","LU0096364046.USD","BK4127","LU2750360641.GBP","LU0251142724.SGD","LU0345770993.USD","MNSH","LU2471134523.USD","GSX","IE0004091025.USD","BK4533","LU2237438978.USD","LU1894683264.USD","LU0345770308.USD","BK4207","IE00B19Z3581.USD","LU2750360997.AUD","LU0742534661.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657612453","title":"Latigo Biotherapeutics Ups IPO to 19.2 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657612453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657612453?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:17","pubTimestamp":1786097820,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics increased its initial public offering to 19.2 million shares for $18 apiece.The clinical-stage biopharmaceutical company previously planned to sell 16 million shares at between ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRHC","KCE","LTGO","BK4127","REDS","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657693906","title":"Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693906","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657693906?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:03","pubTimestamp":1786060980,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., Aug.  06, 2026  (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medici","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3340893/0/en/latigo-biotherapeutics-announces-pricing-of-upsized-345-6-million-initial-public-offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}